MA53670A - Pyridazinones et leurs procédés d'utilisation - Google Patents
Pyridazinones et leurs procédés d'utilisationInfo
- Publication number
- MA53670A MA53670A MA053670A MA53670A MA53670A MA 53670 A MA53670 A MA 53670A MA 053670 A MA053670 A MA 053670A MA 53670 A MA53670 A MA 53670A MA 53670 A MA53670 A MA 53670A
- Authority
- MA
- Morocco
- Prior art keywords
- pyridazinones
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862732728P | 2018-09-18 | 2018-09-18 | |
PCT/US2019/051680 WO2020061162A1 (en) | 2018-09-18 | 2019-09-18 | Pyridazinones and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
MA53670A true MA53670A (fr) | 2021-07-28 |
MA53670B1 MA53670B1 (fr) | 2024-05-31 |
Family
ID=76217932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA53670A MA53670B1 (fr) | 2018-09-18 | 2019-09-18 | Pyridazinones et leurs procédés d'utilisation |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR116433A1 (es) |
MA (1) | MA53670B1 (es) |
-
2019
- 2019-09-18 MA MA53670A patent/MA53670B1/fr unknown
- 2019-09-18 AR ARP190102652A patent/AR116433A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
MA53670B1 (fr) | 2024-05-31 |
AR116433A1 (es) | 2021-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA55136A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA52753A (fr) | Anticorps anti-sirpa et leurs procédés d'utilisation | |
MA55890A (fr) | Modulateurs de thr-beta et leurs procédés d'utilisation | |
MA44490A (fr) | Adhésifs biocompatibles et leurs procédés d'utilisation | |
MA44524A (fr) | Néoantigènes et leurs procédés d'utilisation | |
MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA51848A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA55885A (fr) | Chélateurs macrocycliques et leurs procédés d'utilisation | |
MA52501A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA52765A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA52496A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA50077A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA48772A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA54538A (fr) | Inhibiteurs d'apol1 et leurs procédés d'utilisation | |
MA54594A (fr) | Stéroïdes neuroactifs et leurs procédés d'utilisation | |
MA44740A (fr) | Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation | |
MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA47499A (fr) | Anticorps anti-tau et leurs procédés d'utilisation | |
MA55381A (fr) | Pyridazinones et leurs procédés d'utilisation | |
MA51837A (fr) | Inhibiteurs de l'arginase et leurs procédés d'utilisation | |
MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
MA53235A (fr) | Indoles substitués et procédés d'utilisation associés | |
MA42409A (fr) | Oxystérols et leurs procédés d'utilisation |